Long-term treatment in bipolar disorder

Journal of Clinical Psychiatry

Volumn 66, Issue 1, 2005, Pages 7-12

  Swann, Alan C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; OLANZAPINE; PLACEBO; TOPIRAMATE; VALPROATE SEMISODIUM; ANTICONVULSIVE AGENT;

ANXIETY; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FAMILY RELATION; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBSTANCE ABUSE; SUICIDAL IDEATION; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FEMALE; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUICIDE;

ACUTE DISEASE; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM; LONG-TERM CARE; PATIENT EDUCATION; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK FACTORS; SUICIDE;

EID: 14544290628     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Cutler NR, Post RM. Life course of illness in untreated manic-depressive patients. Compr Psychiatry 1982;23:101-115
2. Perugi G, Micheli C, Akiskal HS, et al. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr Psychiatry 2000;41:13-18
3. Post RM, Leverich GS, Altshuler LL, et al. An overview of recent findings of the Stanley Foundation Bipolar Network, pt 1. Bipolar Disord 2003;5:310-319
4. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-495
5. Bauer MS, Kirk GF, Gavin C, et al. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J Affect Disord 2001;65:231-241
6. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-181
7. Swann AC, Bowden CL, Calabrese JR, et al. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand 2000;101:444-151
8. Gelenberg AJ, Kane JM, Keller MB. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders. N Engl J Med 1989;321:1489-1493
9. Kessing LV, Hansen MG, Andersen PK, et al. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders: a life-long perspective. Acta Psychiatr Scand 2004;109:339-344
10. Gitlin MJ, Swendsen J, Heller T, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-1640
11. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994;331:591-598
12. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-441
13. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry 2004;184:337-345
14. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1377-1385
15. Altamura AC, Salvadori D, Madaro D, et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord 2003;76:267-271
16. Ghaemi SN, Hsu DJ, Rosenquist KJ, et al. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann Clin Psychiatry 2004;16:69-73
17. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-1169
18. Vanelle JM, Loo H, Galinowski A, et al. Maintenance ECT in intractable manic-depressive illness. Convuls Ther 1994;10:195-205
19. Bowden CL, Calabrese JR, McElroy SL, et al, for the Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-489
20. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400
21. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-1024
22. Tohen M, Bowden C, Calabrese J, et al. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month clinical trial. Eur Neuropsychopharm 2003;13(suppl 4):S212-S213
23. Tohen M, Greil W, Calabrese JR, et al. Olanzapine vs lithium in relapse/recurrence prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Am J Psychiatry. In press
24. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-1271
25. Greenhouse JB, Stangl D, Kupfer DJ, et al. Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry 1991;48:313-318
26. DerSimonian R, Levine RJ. Resolving discrepancies between a meta-analysis and a subsequent large controlled trial. JAMA 1999;282:664-670
27. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159:1155-1159
28. Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postarad Med 2000;Spec No:1-104
29. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993;50:448-455
30. Bowden CL, Swann AC, Calabrese JR, et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997;33:693-699
31. Coryell W, Winokur G, Solomon DA, et al. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med 1997;27:281-289
32. Harrow M, Goldberg JF, Grossman LS, et al. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990;47:665-671
33. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001;62:565-569
34. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470-478
35. Frank E, Thase ME. Natural history and preventative treatment of recurrent mood disorders. Annu Rev Med 1999;50:453-468
36. Frank E, Hlastala S, Ritenour A, et al. Inducing lifestyle regularity in recovering bipolar disorder patients: results from maintenance therapies in bipolar disorder protocol. Biol Psychiatry 1997;41:1165-1173
37. Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness: efficacy, effectiveness, and efficiency. Br J Psychiatry 1994;164:741-746
38. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders, 5: a double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976;33:117-120
39. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 1976;133:925-929
40. Prien RF, Klett CJ, Caffey EM Jr. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 1974;131:198-203
41. Thase ME, Bhargava M, Sachs GS. Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach. Psychiatr Clin North Am 2003;26:495-518
42. Joffe RT, MacQueen GM, Marriott M, et al. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002;105:427-430
43. Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J Affect Disord 2001;64:99-106
44. Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-433
45. Altshuler L, Kiriakos L, Calcagno J, et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001;62:612-616
46. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003;160:1252-1262
47. Ghaemi SN, Goodwin FK. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs lithium in the setting of minimal antidepressant use. J Affect Disord 2001;65:281-287
48. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996;16(suppl 1):32S-47S
49. Schweizer E, Dever A, Clary C. Suicide upon recovery from depression: a clinical note. J Nerv Ment Dis 1988;176:633-636
50. Fava GA, Kellner R. Prodromal symptoms in affective disorders. Am J Psychiatry 1991;148:823-830
51. Novacek J, Raskin R. Recognition of warning signs: a consideration for cost-effective treatment of severe mental illness. Psychiatr Serv 1998;49:376-378
52. Lam D, Wong G, Sham P. Prodromes, coping strategies and course of illness in bipolar affective disorder: a naturalistic study. Psychol Med 2001;31:1397-1402
53. Wittchen HU, Mhlig S, Pezawas L. Natural course and burden of bipolar disorders. Int J Neuropsychopharmacol 2003;6:145-154
54. Post RM, Roy Byrne PP, Uhde TW. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry 1988;145:844-848
55. Freeman MP, Smith KW, Freeman SA, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002;63:284-287
56. Viguera AC, Cohen LS. The course and management of bipolar disorder during pregnancy. Psychopharmacol Bull 1998;34:339-346
57. Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998;59(suppl 6):57-64
58. Sitland Marken PA, Rickman LA, Wells BG, et al. Pharmacologic management of acute mania in pregnancy. J Clin Psychopharmacol 1989;9:78-87
59. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-450
60. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998;59:405-414
61. Maser JD, Akiskal HS, Schettler P, et al. Can temperament identify affectively ill patients who engage in lethal or near-lethal suicidal behavior? a 14-year prospective study. Suicide Life Threat Behav 2002;32:10-32
62. Swann AC, Dougherty DM, Pazzaglia PJ, et al. Impulsivity: a link between bipolar disorder and substance abuse. Bipolar Disord 2004;6:204-212
63. O'Connell RA, Mayo JA, Flatow L, et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123-129
64. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999;60(suppl 2):53-56
65. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidally in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
66. Sachs GS, Yan LJ, Swann AC, et al. Integration of suicide prevention into outpatient management of bipolar disorder. J Clin Psychiatry 2001;62(suppl 25):3-11
67. Coppen A. Depression as a lethal disease: prevention strategies. J Clin Psychiatry 1994;55(suppl 4):37-45